Hjem
Beryl Leirvaags bilde

Beryl Leirvaag

Overingeniør, Mohn kreftforskningslaboratorium
  • E-postBeryl.Leirvaag@uib.no
  • Telefon+47 55 97 64 44+47 917 73 754
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    Rom 
    1417, etg. 1M Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) 2020. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology. 1-10.
  • Vis forfatter(e) 2016. Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice. 4 sider.
  • Vis forfatter(e) 2015. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 1553-1564.
  • Vis forfatter(e) 2012. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 sider.

Se fullstendig oversikt over publikasjoner i CRIStin.